17 research outputs found
Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis
Get PDFChange from baseline in swollen (a) and tender (b) joint counts. *Error bars show upper SE for placebo and lower SE for namilumab. SE standard error, SJC swollen joint count, TJC tender joint count. (PDF 1292 kb
Milk: a postnatal imprinting system stabilizing FoxP3 expression and regulatory T cell differentiation
Full text linkMicrobiota‐Dependent Involvement of Th17 Cells in Murine Models of Inflammatory Arthritis
No full text
The effect of Wazzup Mama?! An antenatal intervention to prevent or reduce maternal distress in pregnancy
No full textThe Boundaries of Liberation, the Chains of Freedom: Urban Women in 1960s Egyptian Popular Cinema
No full text
Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis
No full textGM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential
No full textNeutrophil extracellular traps in the host defense against sepsis induced by Burkholderia pseudomallei (melioidosis)
No full text
